Sunvozertinib
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Sunvozertinib
- Molecular weight
- 584.1
- Structure (SMILES)
- C=CC(=O)Nc1cc(Nc2nccc(Nc3cc(Cl)c(F)cc3C(C)(C)O)n2)c(OC)cc1N1CC[C@@H](N(C)C)C1
- [14C]-DZD9008
- 122507
- 14c dzd9008
- a 1801
- A-1801
- a1801
- A1801
- asym 122507
- ASYM-122507
- dz 0586
- DZ-0586
- DZ'0586
- dz00000586
- DZ00000586
- dz0586
- DZ0586
- dzd 9008
- DZD-9008
- dzd9008
- Dzd9008
- DZD9008
- dzd9008 and carbamazepine
- dzd9008 and intraconazole
- dzd9008 azd4205
- dzd9008 plus bevacizumab
And 12 more, listed on the interactive page.
- CAS registry numbers
- 2370013-12-8
- ChEMBL ID
- CHEMBL5314564
- InChIKey
- BTMKEDDEMKKSEF-QGZVFWFLSA-N
- PubChem compound IDs
- 139377809
- RxNorm IDs (RxCUI)
- 2719226
- FDA ingredient codes (UNII)
- L1Q2K5JYO8
- Patents
- 3
- Designations
- 6
- Earliest recorded loss of exclusivity
- 28 Jan 2039
- First in class
- No
- Fast track
- No
- Breakthrough designation
- Yes
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- Yes
- Pharmacology name
- sunvozertinib
- Type
- Synthetic organic
- Drug name stem
- -tinib
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- epidermal growth factor receptor
- Gene symbol
- EGFR
- Protein identifier
- P00533
- Median affinity
- 7.09
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Bruton tyrosine kinase
- Gene symbol
- BTK
- Protein identifier
- Q06187
- Median affinity
- 8.54
- Affinity units
- pIC50
- Condition
- Lymphoma, Follicular
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000096
- Subject identifier
- D008224
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition identifier
- EFO_0000096
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0015759
- Highest recorded phase
- 1
- NCT03974022
- NCT05668988
- NCT05712902
- NCT05926180
- NCT06182761
- NCT06195189
- NCT06276283
- NCT06295432
- NCT06348927
- NCT06355609
- NCT04148742
- NCT06084104
- Hydrogen bond acceptors
- 9
- Hydrogen bond donors
- 4
- Polar surface area
- 114.88
- Calculated partition coefficient (ALogP)
- 5.26
- Calculated partition coefficient (XLogP)
- 5
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 10
- Heavy atoms
- 41
- Molecular formula
- C29H35ClFN7O3
- Monoisotopic mass
- 583.2473939
- Natural product
- No
- Recorded assays
- 24
- Active assays
- 17
Active assay types
- Confirmatory
Related records
Trials (20)
- A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
- A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)
- A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
- Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)
- Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)
- Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
- Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)
- Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult Participants
- Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine
- DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
- DZD9008 PK Study in Hepatic Impairment Subjects
- Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation.
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
- Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC
- Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure
- Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
- Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)
- Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II
- Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
In development for (4)
- B-cell non-Hodgkin lymphoma Phase 1
- Liver disorder Phase 1
- Neoplasm of mature B-cells Phase 1
- Non-small cell lung carcinoma Phase 3